The International Science of Health Journal
Vol.2, No. 2 June 2024
e-ISSN: 2986-6820; p-ISSN: 2986-6855, Pages 117-127
DOI: https://doi.org/10.59680/ishel.v2i2.1161

Vitamin D3 And Irritable Bowel Syndrome: Review

Maryam Kadhim Al-Shemery
Department Of Pathological Analysis, College Of Science, University Of Kufa. Iraq

Fatema Ali Al Kafhage
College Of Veterinary Medicine, University Of Karbala. Iraq

Rusul Ali Al-Masaoodi
College Of Applied Medical Sciences, University Of Kerbala, Kerbala, Iraq
Corresponding author : shemeriya1992@gmail.com

Abstract. *Irritable bowel illness is a widespread health ailment that affects almost every age group around the world. The pathogenesis of IBS is still poorly understood. It is a prevalent dysfunctional bowel condition marked by recurring stomach pain or discomfort and changed bowel habits. A central concept is that IBS symptoms are caused by a bilateral imbalance of brain-gut connections, which appears as increased gut sensation and changed bowel patterns. The purpose of the review is to determine the role of vitamin D levels in people with irritable bowel syndrome patients. Vitamin D, which plays a role in inflammatory processes, can affect a variety of pathways implicated in the appearance of IBS. Vitamin D insufficiency was shown to be greater in the IBS group, indicating a relationship between vitamins.*

Keyword: *Vitamin, Irritable Bowel Syndrome, IBS, D3, calcifediol*

Introduction

Being a permanent physiological condition, IBS, also called irritable bowel syndrome, significantly interferes with the individual's capacity to go about their daily lives with jobs due to modifications to the digestive system and discomfort in the abdomen. It mostly impacts youthful, female people, for tends to coexist alongside additional fundamental digestive diseases (FGIDs). It significantly impairs quality of living or the financial health of a community (1,2).

irritable bowel is categorized as an FGID, which indicates no particular anatomical as well as physiological defect that may be responsible for the symptoms of digestion that it causes. The previously Italy intravenous (IV standards characterize irritable bowel as persistent abdominal discomfort the fact that happened, upon a typical basis, at least a single afternoon every seven days within the last three months and involved more than one different connected symptom—defecation, alteration in the frequency range, as well as evolution through appearance—are used to in medicine diagnose the condition (3).

According to the Bath Feces Formulation range (BSFS), which rates the texture of stool on a range of one to seven (tirelessly through mushy), IBS may be further categorized by subgroups

Received: April 02, 2024; Accepted: May 06, 2024; Published: June 31, 2024
* *Maryam Kadhim Al-Shemery shemeriya1992@gmail.com*

(4). IBS can be divided into four subcategories: irritable bowel without heterogeneous bowel behaviors (IBS-M), IBS having dominant constipation (IBS-C), IBS involving predominant diarrhea (IBS-D), or unexplained irritable bowel (IBS-U). In BSFS, the treatment of IBS is usually associated with variety two or three whereas IBS with diarrhea for variety six to seven. People suffering from IBS m might experience symptoms of either constipation or diarrhea. IBS-U does not fit into any of the additional categories (5), however, it does match the criteria for diagnosis of IBS.

Widespread psychological disorders including depression and anxiousness were very prevalent around the world even were a major contributor to impairment of death (6). These conditions were commonly linked to irritable bowel and research suggests IBS sufferers may be more susceptible to anxiety and depression (7). Throughout the preceding couple of centuries, sadness and feelings of anxiety have become more common (8). The overall incidence of severe depression and anxiety disorders climbed by an estimated twenty-eight percent and twenty-six percent during the year 2020 (9), with the COVID-19 pandemic having exacerbated this rise in diagnoses. Additionally, it appears that as doctors become more aware of IBS, westernization, as well as dietary and lifestyle modifications, the disease's predominance continues to rise (10). One of the gastrointestinal symptoms of post-acute COVID-19 syndrome is likewise IBS (11). It is imperative to talk about how to modify current therapies to better serve the requirements of individuals with coexisting mental health disorders including IBS regarding the possible rise in their prevalence worldwide. (12)

- **Immune Responses, and Pain in IBS**

Research from human as well as animal investigations suggests that abdominal heightened sensitivity, a low degree moderate inflammatory processes, with elevated intestinal permeability interact leading to irritable bowel syndrome (IBS). Many research (13–16) have documented enhanced proliferation of mast cell involvement in the gastrointestinal mucosal with IBS individuals, whereas various studies (17–18) have not at all. In colonic alongside jejunal sampling the waste products collected from IBS-D and IBS-C individuals, greater levels of mast cell intermediaries, among them histamine, have an enzyme called a try, as well as trypsin enzyme were detected from research which discovered arises within mast numbers of cells (19) alongside studies which found there was no rise in mast's cell measurements (17, 18). Several investigations have shown that people with IBS have considerably higher levels of mast cell populations as well as total immunocytes, CD3+, CD4+, and CD8+ T cells when juxtaposed with normal controls (20). Stress-related malfunction that affects the colonic barrier within rats is accompanied by several

changes, including increased concentration of mast cell population near nerve impulses (23), raised more mucosal stimulation along with synaptic development (23), while hyperplasia or proliferation of mast cells within the tissue (21, 22). By controlling the production of TJ amino acids, the activity of specific gastrointestinal nervous system pathways—possibly through mast cell mediation and serotonin—may have a role in the regulation of intestine epithelial permeability. (24)

- **Vitamin D (VD)**

As a lipid-soluble steroid, sunlight-sensitive vitamin D (VD) is essential for controlling the absorption of calcium and phosphorus (25). People are primary consumers that two different kinds of vitamin D that have comparable functions: D2 as well as D3, or the supplement ergo as well as cholesterol, correspondingly. However, according to current research, VD2 appears to have been eliminated through the cells more quickly with the voltage level VD3 based on biochemical markers. D2's effectiveness with the identical amount is approximately one-third to fifty percent as much as vitamin D3. aesthetically speaking, we prefer to use VD3 in addition to VD (26). Research has revealed a robust association between VD and type 1 diabetes (27, 28) in addition to overweight (29).

The hormone also known as vitamin D plays two important functions across the organism: it helps the human body absorb phosphate and calcium and regulates the production of parathyroid hormone. The 25-hydroxyvitamin D (25(OH)D; calcifediol) was the primary type that D that is circulation and is employed throughout medical settings to assess vitamin D sufficiency. (30) The healthcare sector is showing an increasing interest in D, mostly because of the reported shortage in several systematic illnesses. It is well-established in medicine that vitamin D is linked to both skeletal as well as extra-skeletal functions (31). Shortage may originate through reduced skin manufacturing as well as malabsorption of the vitamin. Vitamin D is frequently created in the human body through exposure to sunlight or obtained through dietary habits, which includes a fish-based and dairy product-heavy diet. Research indicates the antioxidant as being essential for regulating more than two hundred gene associated with the regulation of cell cycles, which includes apoptotic distinctions, along with proliferative. subsequently is commonly known because the vast majority of connective tissue, including the circulatory system, neurological structure, and even stomach, contain vitamin-D receptors. (25) The voltage level VD insufficiency is intimately associated with the onset, progression, along consequences of irritable bowel Studies by Khayyat and Attar (34) and Nwosu et al. (32) and Cho et al. (33) revealed that the VD concentrations were either inadequate or not enough among

people having IBS. Additionally, qualitative research has determined that as many as 82 percent of those suffering from IBS exhibit a VD deficit. (35)
Through enhancing the microbes in the intestines, V d could have an immunomodulatory agents effect. A primary interface that connects laboratory as well as in vivo scenarios involves the gastrointestinal epithelium membrane (IEB) (36). It is in charge of protecting against dangerous materials in along with collecting nutrients and water.
Fluid is held in place with the IEB, and materials are transferred via paracellular and interstitial channels. In the meantime, certain gut bacteria can control the accessibility of IEB as well as emitting short-chain aromatic hydrocarbons like butyrate; it is the chemical propionate as well as acetic (37). Inflammatory conditions are caused by an imbalance of bacteria in the gut, which results in a rise in lipopolysaccharide-producing Enterobacteriaceae along with a reduction in short-chain aliphatic hydrocarbon-producing Phaecococcus, and Coprococcus (38). This imbalance favors beneficial reactions over anti-inflammation reactions.
Moreover, the bacteria Faecalibacterium prausnitzii improves the equilibrium of intestinal inflammation by elevating the compound butyrate synthesis, resulting in amplification of Treg cells, also known as regulatory T cells (39). IBS-related and can be triggered by alterations in intestinal movement as well as permeation, immunological reacting, abdominal responsiveness, including gut microbiota composition brought on by psychological strain (40).

- **Vitamin D supplementation**

The neurological system including the gastrointestinal tract are the sites of expression for vitamin D receptors (VDR), and its stimulation is associated with amounts of neurotransmitters, the creation of serotonin, gastrointestinal epithelium permeability, including gastrointestinal inflammation. (41-43) Additionally, when 25, (OH)D-VDR combination binds, 1-a1pha-hydroxy1ase is expressed, and this enzyme changes 25 (OH)D into 1, 25-dihydroxy vitamin D (44). It was demonstrated that this 25 (OH)D compound increases neutrophils, and thus promotes nerve cell development and longevity. 45
As a consequence, the results of our investigation suggest that sunlight could have immediate effects on gut health and brain development, which could result in better IBS signs as well as a standard of life. In addition to depressive symptoms, vitamin D insufficiency is also linked or indicated in the development and progression of bowel inflammation along with colorectal cancer, which is two digestive tract disorders. To yet, no research investigations research epidemiological analyses are investigating into a possible connection to IBS. (46) Teenagers with IBS may benefit from taking supplements of vitamin D regularly. (47)

An investigation involving an IBS sufferer receiving an excessive quantity of vitamin D supplements (3000 IU every day) was recently released. The person surveyed indicated that after using supplements, their signs of IBS subsided; however, after they stopped taking supplements, the signs returned. Furthermore, a review of 37 IBS sufferers' online posts (blogs and forums) revealed that seventy percent they have claimed stated taking supplements had improved their signs of illness, although most of the respondents had previously been reportedly vitamin D linking vitamin D deficiencies to IBD (inflammatory bowel disease) further bolster the significance that supplements play in digestive system wellness (48,49) A recent comprehensive study revealed that vitamin D supplements may help people with IBD. (50)

In a study on IBS adult patients, vitamin D supplementation was provided for 6 months at a dose of 50,000 IU weekly that effectively raised serum 25 (OH)D_3 levels more than 2.5 times than the baseline and significantly reduced the mean IBS-SSS score in vitamin D treatment group. (51) This was similar to our results, however, the mean rise of serum levels of vitamin D in their study was more than ours which could be due to a higher dose of vitamin D used in their study. In contrast to our findings, Tazzyman et al. (52) found that twelve months of sunlight VD implementation. did not significantly reduce the signs of IBS in people with the condition. Because it was a pilot trial with fifty individuals divided into three separate weapons, it lacked the potential for yielding meaningful results.

Supplementing with vitamin D might serve as a viable treatment for IBS, addressing various facets that contribute to the disease's etiology. Numerous first-line treatments that focus on the most common signs of IBS, like loperamide that for diarrhoea (53), fibers that dissolve that defecation (54, 55), nor antispasmodic medications for stomach discomfort (56), are effective in treating some of the signs and symptoms but not all of the disorders. With time, indicators of IBS can change (57, 58). Thus, compared to concentrating on one of the condition's most common indicators, creating for an additional tailored yet accurate course of action for IBS ought to tackle the condition's fundamental pathophysiology (59). In addition, vitamin D could assist achieve this aim. Comparing our findings to the earlier analyses, we found reduced difficulties with methodology. During the preceding 20 years, Rome's criteria for determining the presence of IBS have been changed beyond I through IV (60). Through inhibiting the activity of T helper 1 and T helper 17 lymphocytes (61, 62) while reducing its interleukin-23 receptor cascade in lymphocytes of innate origin (63), the antioxidant vitamin D has also shown therapeutic properties.

Reference

Yang, W., Yang, X., Cai, X., Zhou, Z., Yao, H., Song, X., ... & Xiong, P. (2022). The prevalence of irritable bowel syndrome among Chinese university students: a systematic review and meta-analysis. *Frontiers in Public Health*, *10*, 864721.

Roisinblit KC. (2013) irritable bowel syndrome in women. *J Midwifery Womens Health* ,58:15–24; quiz 116.

Lacy, B. E., & Patel, N. K. (2017). Rome criteria and a diagnostic approach to irritable bowel syndrome. *Journal of clinical medicine*, *6*(11), 99.

Ford, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M. (2020). Functional gastrointestinal disorders 2 irritable bowel syndrome. *Lancet*, *396*(10263), 1675-1688.

Ford, A.C.; Lacy, B.E.; Talley, N.J. (2017). Irritable Bowel Syndrome. *N. Engl. J. Med.*, 376, 2566–2578.

Depression, W. H. O. (2017). Other common mental disorders: global health estimates. *Geneva: World Health Organization*, *24*.

Zamani, M., Alizadeh-Tabari, S., & Zamani, V. (2019). Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. *Alimentary pharmacology & therapeutics*, *50*(2), 132-143.

Liu, Q., He, H., Yang, J., Feng, X., Zhao, F., & Lyu, J. (2020). Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study. *Journal of psychiatric research*, *126*, 134-140.

Santomauro, D. F., Herrera, A. M. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M., ... & Ferrari, A. J. (2021). Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *The Lancet*, *398*(10312), 1700-1712.

Black, C. J. & Ford, A. C. Global burden of irritable bowel syndrome: trends, predictions and risk factors. *Nat. Rev. Gastroenterol. Hepatol.* 17, 473–486 (2020).

Meringer, H. & Mehandru, S. Gastrointestinal post-acute COVID-19 syndrome. *Nat. Rev. Gastroenterol. Hepatol.* 19, 345–346 (2022).

Staudacher, H. M., Black, C. J., Teasdale, S. B., Mikocka-Walus, A., & Keefer, L. (2023). Irritable bowel syndrome and mental health comorbidity—approach to multidisciplinary management. *Nature Reviews Gastroenterology & Hepatology*, 1-15.

Coeffier M, Gloro R, Boukhettala N, Aziz M, Lecleire S, Vandaele N, Antonietti M, Savoye G, Bole-Feysot C, Dechelotte P, Reimund JM, Ducrotte P. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol *105*: 1181–1188, 2010.

Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De Giorgio R, Stanghellini V, Grundy D, Tonini M, De Ponti F, Corinaldesi R, Barbara G. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol *106*: 1290–1298, 2011.

Martinez C, Vicario M, Ramos L, Lobo B, Mosquera JL, Alonso C, Sanchez A, Guilarte M, Antolin M, de Torres I, Gonzalez-Castro AM, Pigrau M, Saperas E, Azpiroz F, Santos J. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol *107*: 736–746, 2012.

Vivinus-Nébot M, Dainese R, Anty R, Saint-Paul MC, Nano JL, Gonthier N, Marjoux S, Frin-Mathy G, Bernard G, Hebuterne X, Tran A, Theodorou V, Piche T. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol *107*: 75–81, 2012.

Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest *117*: 636–647, 2007

Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC, van den Wijngaard RM, Boeckxstaens GE. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut *59*: 1213–1221, 2010.

Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, Bunnett NW, Grundy D, Corinaldesi R. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology *132*: 26–37, 2007.

hman L, Isaksson S, Lindmark AC, Posserud I, Stotzer PO, Strid H, Sjovall H, Simren M. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol *104*: 1205–1212, 2009.

Santos J, Yang PC, Soderholm JD, Benjamin M, Perdue MH. Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat. Gut *48*: 630–636, 2001.

Barreau F, Ferrier L, Fioramonti J, Bueno L. Neonatal maternal deprivation triggers long term alterations in colonic epithelial barrier and mucosal immunity in rats. Gut *53*: 501–506, 2004.

Barreau F, Salvador-Cartier C, Houdeau E, Bueno L, Fioramonti J. Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats. Gut *57*: 582–590, 2008.

Neunlist M, Toumi F, Oreschkova T, Denis M, Leborgne J, Laboisse CL, Galmiche JP, Jarry A. Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways. Am J Physiol Gastrointest Liver Physiol *285*: G1028–G1036, 2003.

Vitamin, D. (2007). deficiency. Holick MF. *N Engl J Med*, *357*, 266-281.

Munns, C. F., Shaw, N., Kiely, M., Specker, B. L., Thacher, T. D., Ozono, K., ... & Högler, W. (2016). Global consensus recommendations on prevention and management of nutritional rickets. *The Journal of Clinical Endocrinology & Metabolism*, *101*(2), 394-415.

Liu, C., Lu, M., Xia, X., Wang, J., Wan, Y., He, L., & Li, M. (2015). Correlation of serum vitamin D level with type 1 diabetes mellitus in children: a meta-analysis. *Nutricion hospitalaria*, *32*(4), 1591-1594.

He, L. P., Song, Y. X., Zhu, T., Gu, W., & Liu, C. W. (2022). Progress in the relationship between vitamin D deficiency and the incidence of type 1 diabetes mellitus in children. *Journal of Diabetes Research*, *2022*.

Yao, Y., Zhu, L., He, L., Duan, Y., Liang, W., Nie, Z., ... & Fang, Y. (2015). A meta-analysis of the relationship between vitamin D deficiency and obesity. *International journal of clinical and experimental medicine*, *8*(9), 14977.

Holick, M. F. (Ed.). (2010). *Vitamin D: physiology, molecular biology, and clinical applications*. Springer Science & Business Media.

Attar, S. M., & Siddiqui, A. M. (2013). Vitamin d deficiency in patients with systemic lupus erythematosus. *Oman medical journal*, *28*(1), 42.

Nwosu, B. U., Maranda, L., & Candela, N. (2017). Vitamin D status in pediatric irritable bowel syndrome. *PLoS One*, *12*(2), e0172183.

Cho, Y., Lee, Y., Choi, Y., & Jeong, S. (2018). Association of the vitamin D level and quality of school life in adolescents with irritable bowel syndrome. *Journal of clinical medicine*, *7*(12), 500.

Khayyat, Y., & Attar, S. (2015). Vitamin D deficiency in patients with irritable bowel syndrome: does it exist?. *Oman medical journal*, *30*(2), 115.

Chong, R. I. H., Yaow, C. Y. L., Loh, C. Y. L., Teoh, S. E., Masuda, Y., Ng, W. K., ... & Ng, Q. X. (2022). Vitamin D supplementation for irritable bowel syndrome: A systematic review and meta-analysis. *Journal of Gastroenterology and Hepatology*, *37*(6), 993-1003.

Turner, J. R. (2009). Intestinal mucosal barrier function in health and disease. *Nature reviews immunology*, *9*(11), 799-809.

Barbara, G., Barbaro, M. R., Fuschi, D., Palombo, M., Falangone, F., Cremon, C., ... & Stanghellini, V. (2021). Inflammatory and microbiota-related regulation of the intestinal epithelial barrier. *Frontiers in nutrition*, *8*, 718356.

Wellington, V. N. A., Sundaram, V. L., Singh, S., & Sundaram, U. (2021). Dietary supplementation with vitamin d, fish oil or resveratrol modulates the gut microbiome in inflammatory bowel disease. *International Journal of Molecular Sciences*, *23*(1), 206.

Tang, H. Y., Jiang, A. J., Wang, X. Y., Wang, H., Guan, Y. Y., Li, F., & Shen, G. M. (2021). Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review. *Annals of Translational Medicine*, *9*(14).

Zhang, Z., Yang, X., Jia, Y., Wen, Y., Cheng, S., Meng, P., ... & Zhang, F. (2021). Vitamin D and the risks of depression and anxiety: an observational analysis and genome-wide environment interaction study. *Nutrients*, *13*(10), 3343.

Patrick, R. P., & Ames, B. N. (2014). Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. *The FASEB Journal*, *28*(6), 2398-2413.

Kong, J., Zhang, Z., Musch, M. W., Ning, G., Sun, J., Hart, J., ... & Li, Y. C. (2008). Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, *294*(1), G208-G216.

Li, Y. C., Chen, Y., & Du, J. (2015). Critical roles of intestinal epithelial vitamin D receptor signaling in controlling gut mucosal inflammation. *The Journal of steroid biochemistry and molecular biology*, *148*, 179-183.

Zehnder, D., Bland, R., Williams, M. C., McNinch, R. W., Howie, A. J., Stewart, P. M., & Hewison, M. (2001). Extrarenal expression of 25-hydroxyvitamin D3-1α-hydroxylase. *The Journal of Clinical Endocrinology & Metabolism*, *86*(2), 888-894.

McCann, J. C., & Ames, B. N. (2008). Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction?. *The FASEB Journal*, *22*(4), 982-1001.

Tazzyman, S., Richards, N., Trueman, A. R., Evans, A. L., Grant, V. A., Garaiova, I., ... & Corfe, B. M. (2015). Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: outcomes from a pilot trial. *BMJ open gastroenterology*, *2*(1), e000052.

El Amrousy, D., Hassan, S., El Ashry, H., Yousef, M., & Hodeib, H. (2018). Vitamin D supplementation in adolescents with irritable bowel syndrome: Is it useful? A randomized controlled trial. *Saudi Journal of Gastroenterology*, *24*(2), 109-114.

Sprake, E. F., Grant, V. A., & Corfe, B. M. (2012). Vitamin D3 as a novel treatment for irritable bowel syndrome: single case leads to critical analysis of patient-centred data. *Case Reports*, *2012*, bcr-2012.

Hlavaty, T., Krajcovicova, A., Koller, T., Toth, J., Nevidanska, M., Huorka, M., & Payer, J. (2014). Higher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseases. *World journal of gastroenterology: WJG*, *20*(42), 15787.

Nicholson, I., Dalzell, A. M., & El-Matary, W. (2012). Vitamin D as a therapy for colitis: a systematic review. *Journal of Crohn's and Colitis*, *6*(4), 405-411.

Casseb, G. A., Kaster, M. P., & Rodrigues, A. L. S. (2019). Potential role of vitamin D for the management of depression and anxiety. *CNS drugs*, *33*(7), 619-637.

Black CJ, Thakur ER, Houghton LA, Quigley EMM, Moayyedi P, Ford AC. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2020;69:1441–51

Cann, P. A., Read, N. W., Holdsworth, C. D., & Barends, D. (1984). Role of loperamide and placebo in management of irritable bowel syndrome (IBS). *Digestive diseases and sciences*, *29*, 239-247.

Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., ... & Quigley, E. M. (2014). American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. *Official journal of the American College of Gastroenterology| ACG*, *109*, S2-S26.

Bijkerk, C. J., De Wit, N. J., Muris, J. W. M., Whorwell, P. J., Knottnerus, J. A., & Hoes, A. W. (2009). Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. *Bmj*, *339*.

Ford, A. C., Talley, N. J., Spiegel, B. M., Foxx-Orenstein, A. E., Schiller, L., Quigley, E. M., & Moayyedi, P. (2008). Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. *Bmj*, *337*.

Engsbro, A. L., Simren, M., & Bytzer, P. (2012). Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. *Alimentary pharmacology & therapeutics*, *35*(3), 350-359.

Drossman, D. A., Morris, C. B., Hu, Y., Toner, B. B., Diamant, N., Leserman, J., ... & Bangdiwala, S. I. (2005). A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. *Gastroenterology*, *128*(3), 580-589.

Lacy, B. E., & Patel, N. K. (2017). Rome criteria and a diagnostic approach to irritable bowel syndrome. *Journal of clinical medicine*, *6*(11), 99.

Camilleri, M., Shin, A., Busciglio, I., Carlson, P., Acosta, A., Bharucha, A. E., ... & Zinsmeister, A. R. (2014). Validating biomarkers of treatable mechanisms in irritable bowel syndrome. *Neurogastroenterology & Motility*, *26*(12), 1677-1685.

Cantorna, M. T., Snyder, L., Lin, Y. D., & Yang, L. (2015). Vitamin D and 1, 25 (OH) 2D regulation of T cells. *Nutrients*, *7*(4), 3011-3021.

Zhang, H., Wu, H., Liu, L., Li, H., Shih, D. Q., & Zhang, X. (2015). 1, 25-dihydroxyvitamin D3 regulates the development of chronic colitis by modulating both T helper (Th) 1 and Th17 activation. *Apmis*, *123*(6), 490-501.

Konya V, Czarnewski P, Forkel M, Rao A, Kokkinou E, Villablanca EJ, et al. Vitamin D downregulates the IL-23 receptor pathway in human mucosal group 3 innate lymphoid cells. J Allergy Clin Immunol. 2018; 141:279–92.